Ind-Swift Laboratories Ltd

Ind-Swift Laboratories Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 01 June 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 13 June 2026, providing investors with the most up-to-date view of the company’s performance and outlook.

Ind-Swift Laboratories Ltd has seen its investment rating upgraded from Sell to Hold, reflecting a notable improvement in technical indicators and recent financial results. The upgrade, effective from 1 June 2026, is driven by enhanced technical trends, robust quarterly sales growth, and a strong market performance relative to benchmarks, despite lingering concerns over long-term fundamentals and profitability.

Ind-Swift Laboratories Ltd has witnessed a significant shift in its technical momentum, moving from a mildly bullish stance to a more confident bullish trend. This change is underscored by strong weekly and monthly MACD signals, bullish moving averages, and a notable 8.00% gain in a single trading session, signalling renewed investor interest in this micro-cap pharmaceutical player.

With a surge to Rs 166.85 on 1 Jun 2026, Ind-Swift Laboratories Ltd has reached a fresh 52-week high, marking a remarkable 95.55% gain over the past year. This milestone is underpinned by a confluence of technical indicators signalling sustained momentum, even as the broader Sensex trades near its own lows.

Ind-Swift Laboratories Ltd is rated Sell by MarketsMOJO, with this rating last updated on 27 Apr 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 31 May 2026, providing investors with the latest insights into the company’s fundamentals, valuation, financial trends, and technical outlook.

Ind-Swift Laboratories Ltd., a Chandigarh-based active pharmaceutical ingredients (API) manufacturer, reported a consolidated net profit of ₹15.11 crores for Q4 FY26 (Mar'26), marking a significant 58.39% quarter-on-quarter improvement from ₹9.54 crores in Q3 FY26 (Dec'25). However, on a year-on-year basis, the profit declined sharply by 93.20% from an exceptional ₹222.27 crores in Q4 FY25, which was inflated by extraordinary gains. The company's stock surged 12.68% to ₹151.95 following the results announcement, reflecting investor optimism about the operational turnaround.

Surging past its previous peaks, Ind-Swift Laboratories Ltd touched a fresh 52-week high of Rs 158.15 on 29 May 2026, marking a remarkable rally that has more than doubled its share price from the low of Rs 77.09 recorded last year. This milestone underscores the stock’s strong price momentum amid a mixed broader market backdrop.

Ind-Swift Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 27 Apr 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 20 May 2026, providing investors with the latest insights into the company's performance and outlook.

Ind-Swift Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 27 Apr 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 09 May 2026, providing investors with the latest insights into the company’s performance and outlook.

Ind-Swift Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 27 Apr 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 09 May 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Ind-Swift Laboratories Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Hold to Sell as of 27 April 2026. This change reflects a complex interplay of deteriorating financial fundamentals, cautious valuation metrics, and a shift in technical indicators, despite the company’s strong recent stock performance and positive quarterly results.

Ind-Swift Laboratories Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, reflected in a complex interplay of bullish and bearish signals across key indicators. Despite a recent downgrade in daily price performance, the stock’s longer-term metrics suggest a cautiously optimistic outlook, prompting a reassessment of its technical stance from Sell to Hold.

Ind-Swift Laboratories Ltd has seen its investment rating upgraded from Sell to Hold, driven primarily by a marked improvement in technical indicators and encouraging quarterly financial results. Despite lingering concerns over long-term fundamentals and profitability, the stock’s recent performance and technical outlook have prompted a reassessment of its market stance.

Ind-Swift Laboratories Ltd has exhibited a notable shift in price momentum, with technical indicators signalling a transition from mildly bullish to bullish trends. Despite a mixed bag of signals from key metrics such as MACD, RSI, and moving averages, the stock’s recent performance and technical outlook suggest growing investor interest amid a volatile pharmaceutical sector backdrop.

Ind-Swift Laboratories Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Hold to Sell as of 17 Apr 2026. Despite recent positive quarterly results, the company’s long-term fundamentals and valuation concerns have weighed heavily on the decision, reflected in a MarketsMOJO Mojo Score of 44.0 and a Sell grade. This article analyses the four key parameters—Quality, Valuation, Financial Trend, and Technicals—that triggered this rating change.